This brand name is authorized in Croatia, Cyprus, Ecuador, Estonia, Netherlands, South Africa, UK.
The drug TARGINACT contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
C1ENJ2TE6C - OXYCODONE HYDROCHLORIDE
|
|
Oxycodone is a full opioid agonist with no antagonist properties. It has an affinity for kappa, mu and delta opioid receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. The therapeutic effect is mainly analgesic, anxiolytic, antitussive and sedative. |
|
2
|
UNII
F850569PQR - NALOXONE HYDROCHLORIDE
|
|
Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| TARGINACT Prolonged release tablet | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| TARGINACT Prolonged-release tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| N02AA55 | Oxycodone and naloxone | N Nervous system → N02 Analgesics → N02A Opioids → N02AA Natural opium alkaloids |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 5316-MEE-0720 |
| EE | Ravimiamet | 1474275, 1474286, 1474297, 1474309, 1474310, 1474321, 1474332, 1474343, 1474354, 1474365, 1474433, 1474444, 1474455, 1474466, 1474477, 1474488, 1474499, 1474501, 1474512, 1474523, 1474635, 1474646, 1474657, 1474668, 1474679, 1474680, 1474691, 1474703, 1474714, 1474725, 1474736, 1474747, 1474758, 1474769, 1474770, 1474781, 1474792, 1474804, 1474815, 1474826, 1592276, 1592287, 1592298, 1592300, 1592311, 1592322, 1592333, 1592344, 1592355, 1592366, 1592377, 1592388, 1592399, 1592401, 1592412, 1592423, 1592434, 1592445, 1592456, 1592467, 1592535, 1592546, 1592557, 1592568, 1592579, 1592580, 1592591, 1592603, 1592614, 1592625, 1672523, 1672534, 1672545, 1672556, 1672567, 1672578, 1672589, 1672590, 1672602, 1672613, 1672624, 1672635, 1672646, 1672657, 1672668, 1672679, 1672680, 1672691, 1672703, 1672714 |
| GB | Medicines & Healthcare Products Regulatory Agency | 149758, 149761, 158510, 158514, 373899, 373903, 373906, 373914, 377044, 377046, 377048, 377050, 381684, 381688, 381690, 381692 |
| HR | Agencija za lijekove i medicinske proizvode | HR-H-347037202, HR-H-639349110, HR-H-875883221, HR-H-961831038 |
| NL | Z-Index G-Standaard, PRK | 88838, 88846, 90220, 90239 |
| ZA | Health Products Regulatory Authority | 46/2.9/0646, 46/2.9/0647, 46/2.9/0648 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.